Selection criteria.

This editorial highlights that neoadjuvant therapy across a broad population with non-small cell lung cancer (NSCLC) results in as many as 1 in 5 not to proceeding to a surgery for which they were initially eligible, raising the question of how we can be more selective with who receives this approach as early-stage disease, for example, is less likely to benefit. | Zhang, JAMA Oncol 2023